Shilpa Biologicals MD Warns Single-CDMO Dependence Inflates Development Costs by Up to 40%

Over-reliance on a single contract development and manufacturing partner is quietly eroding development budgets and stalling clinical timelines, according to Madhav Bhutada, Managing Director of Shilpa Biologicals. Bhutada puts the cost exposure at up to 40% in additional development spend when biopharma firms concentrate manufacturing dependencies on one large CDMO and engage that partner too late in the development cycle.

The warning is operationally specific. Bhutada's position is that delayed CDMO engagement compounds risk at exactly the stages where process validation and technology transfer decisions carry the most downstream consequence. For QA directors and supply chain leads managing biologics programs, the implication is that partnership architecture deserves the same early-stage scrutiny applied to analytical method development or ICH Q10 quality system design.

The structural argument for diversification rests on capacity risk. Large CDMOs carry full order books, and a single scheduling conflict or regulatory hold at one site can suspend a program with no immediate alternative. Distributing manufacturing across two or more qualified partners introduces redundancy that single-source models cannot provide, and positions sponsors to negotiate more effectively on both cost and timeline commitments.

For procurement and technical operations teams, the practical read is around contracting sequence. Bhutada's framing suggests that CDMO selection should be initiated during early-phase development rather than at the point of scale-up pressure, allowing sufficient time for technology transfer, process characterisation, and site qualification under 21 CFR Part 211 or equivalent GMP frameworks before clinical supply deadlines apply.

Shilpa Biologicals, the biologics subsidiary of Shilpa Medicare, positions itself within this market as a mid-tier CDMO alternative capable of absorbing programs that larger organisations may deprioritise. That context does not diminish the operational validity of Bhutada's argument, but procurement leads should weigh it when assessing the source.

The 40% cost-increase figure, if borne out across a broader dataset, would represent a material input for any biopharma organisation conducting make-versus-buy analysis or reviewing its external manufacturing strategy ahead of a Phase II-to-III transition.